Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

Inhaled formulation layout blue ocean ushered in the harvest period, Health Yuan (600380.SH) 2021 net profit pre-increase

Published Time:

2022-01-18

 

 

1 On the evening of the 14th, Health Yuan (600380.SH) released its 2021 annual performance forecast. It is expected that Health Yuan's net profit attributable to shareholders of the listed company will reach 1.255 to 1.367 billion yuan in 2021, representing a year-on-year increase of 12%-22%; non-net profit will reach 1.141 to 1.237 billion yuan, representing a year-on-year increase of 18%-28%; basic earnings per share will be 0.65-0.7 yuan. The performance growth is in line with expectations.

 

According to the announcement, the growth in performance mainly comes from the significant sales growth of Health Yuan's chemical preparation sector during the reporting period. Sales in key advantageous areas such as respiratory, digestive, gonadotropins, and mental health experienced sustained and rapid year-on-year growth. In addition, the profitability and proportion of high-end specialty raw materials in the raw materials sector have steadily increased, ensuring steady growth in the company's overall performance. Furthermore, due to the sale of all equity in Jiangsu Niko Medical Device Co., Ltd. by the company's subsidiary, Lizhu Group, in 2020, non-recurring gains and losses decreased year-on-year in 2021.

 

In nearly thirty years of development and transformation, Health Yuan Pharmaceutical Group has become an innovative and research-oriented comprehensive pharmaceutical group, currently deploying four innovative, high-barrier complex preparation R&D platforms. The company's business scope covers multiple fields, including chemical preparations, traditional Chinese medicine preparations, chemical raw materials and intermediates, health products, diagnostic reagents and equipment. Among them, the significant increase in inhaled preparations after volume-based procurement has become an important contributing factor to the company's steady growth.

 

In recent years, the respiratory field has been a key R&D area for Health Yuan, with continuous pipeline progress and multiple future highlights. The company's compound ipratropium bromide inhalation solution, budesonide suspension (large specification), and ipratropium bromide inhalation solution (large and small specifications) have successfully entered the national volume-based procurement, successfully opening up the domestic substitution market and securing the company's sales in the inhaled preparation sector for the next three years. Significant volume growth is expected since the implementation of volume-based procurement in October 2021. In the future, Health Yuan's levofloxacin inhalation solution is expected to further increase in volume with channel expansion. At the same time, acetylcysteine inhalation solution, terbutaline nebulization solution, tobramycin inhalation solution, and formoterol fumarate inhalation solution have all been filed for production and are expected to be approved in 2022. Tobramycin is expected to become China's first inhaled antibiotic, targeting the treatment of bronchiectasis (prevalence of 1.2% in people over 40 in China), with broad market prospects.

 

While accelerating business expansion, Health Yuan is actively deploying cutting-edge technologies. Its biopharmaceutical research institute has established six R&D platforms: industrial strain selection, synthetic biology, biocatalysis, fermentation scaling-up, product extraction, and biochemical raw materials. It has gathered a team of more than 60 elite professionals and signed strategic cooperation agreements and confidentiality agreements with Tencent Quantum Laboratory and Shenzhen Institutes of Advanced Technology. Recently, the institute is working hard to upgrade the production strains of two major products: Cephalosporin C and phenylalanine; and is actively cooperating with Tencent Quantum Laboratory to use AI technology to conduct research on the prediction of genomic gene clusters and functional element sequences and metabolic pathway optimization.

 

In a recent institutional investor communication meeting, Health Yuan stated that compared to many Chinese companies currently seeking financing, the company still has advantages in terms of commercialization: years of deep cultivation in the biopharmaceutical field, not only with an excellent scientific research team, but also with a mature pilot test and scaling-up engineering team. In addition, first-class production capacity reserves also provide considerable practical execution space for subsequent cost reduction and efficiency improvement.

 

Analysts believe that the milestone progress made by Health Yuan in inhaled preparations will serve as an efficient "catalyst" for the company's rapid development and growth. Guotai Junan, Guosheng Securities, and other leading institutions have given Health Yuan buy and overweight ratings, respectively.

 

Source: Financial World